England’s NICE Rejects Tecentriq In Triple-Negative Breast Cancer
But the HTA body plans to work with Roche to address issues
NICE draft guidance says that Tecentriq in combination with chemotherapy is not cost effective in untreated advanced triple-negative breast cancer.
